Advice
following an Independent Review Panel
cetuximab (Erbitux) is not recommended for use within NHS Scotland in combination with irinotecan for the treatment of patients with epidermal growth factor receptor (EGFR)- expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- cetuximab (Erbitux)
- SMC ID:
- 155/05
- Indication:
- In combination with irinotecan for the treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- IRP
- Status
- Superseded
- Date advice published
- 10 October 2005
Additional notes
This advice has been superseded by SMC advice No 1012/14.